

1/266




FIG. 1A




FIG. 1B

2/266




FIG. 1C




FIG. 1D

3/266




FIG. 1E




FIG. 1F

4/266




FIG. 1G

5/266





FIG. 1H

6/266

*PE3b temporal nicking.***PE3b editing system: edit-specific nick of the complementary (unedited) DNA strand****FIG. 11**

7/266

Prime editing with any programmable nuclease




FIG. 1J

8/266

Polymerase-dependent synthesis of a replacement strand encoded by the polymerase against the DNA synthesis template and which contains a desired edit. The mechanism is envisioned to operate similarly to prime editing. Additional factors or effectors may be added *in trans* or as fusions to facilitate the reaction as a whole (e.g., (a) a helicase to unwind the DNA at the cut site to make the cut strand with the 3' end available as a primer, (b) a FEN1 to help remove the endogenous strand on the cut strand to drive the reaction towards replacement of the endogenous strand with the synthesized strand, or (c) a nCas9:gRNA complex to create a second site nick on the opposite strand, which may help drive the integration of the synthesized repair through favored cellular repair of the non-edited strand)

FIG. 1K

9/266




FIG. 1L

10/266








FIG. 1M



2
3
4



3426



ॐ
ॐ
ॐ
ॐ
ॐ





FIG. 3D



٤٣٥





FIG. 3F



17/266




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E





FIG. 5



gRNA_0: no extension
gRNA_1: 7 bp template
gRNA_2: 7 bp template
gRNA_3: 8 bp template
gRNA_4: 15 bp template
gRNA_5: 22 bp template





FIG. 6

21/266



gRNA_0: no extension
gRNA_1: 15 bp template




FIG. 7

22/266




FIG. 8

23/266




FIG. 9A




FIG. 9B

24/266




FIG. 9C




FIG. 9D

25/266




FIG. 10





FIG. 11



12
G
F

27/266




FIG. 13





FIG. 14



SECRET

8105

[illegible]

SEQ NO: 790

CAATTGTAGCGTTGATCGCTTTTTCGCTCTCTCAGCCCTGGCTGGCTAAATCTTGGGCCCAGACTGAGCAGCTATGGCAGCAGAGAGAGCC
GTAATATCCGACTACGAAATAAGACGAGAGCTGGGACGGACCCAGCTAGGAACCCCGGCTGTGACTGTGCTACTACCTCTCTCTCTCTCTGGG

B spacer_3 spacer_2 spacer_1
 TCGTTTCTCCACAGGGCGTCGCAGCAAGCTTTCTATAGACAGGGGCTACTATGTCGAGCTCTCTGCACCGGGA TACTGGTTGCACAGTTTTCGCTGGG 3'
A spacer_2 spacer_1
 ATCGACAGAGGTTCTCCGCGACGGTCTGTGTGCAGTAAGAGTCTGTGTCGCGGATCATACAGCTTCGACAGACGTGGCGGCTATGCACCACTCTGTCTAAACGACACC 5' 297

spacer 4 rev spacer 6

spacer_5_rev

858

29/266




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18




FIG. 19




FIG. 20




FIG. 21

33/266





FIG. 22

34/266

gRNA design for contracting trinucleotide repeat sequences



Trinucleotide repeat contraction with TPRT genome editing




FIG. 23

35/266




FIG. 24

gRNA design for peptide tagging genes at endogenous genomic loci




FIG. 25

36/266




FIG. 26A




FIG. 26B

37/266





FIG. 27

38/266




FIG. 28A




FIG. 28B

39/266




FIG. 29A




FIG. 29B





FIG. 29C

programmable codon deletion and truncations		
SEQ ID NO: 811	GFP	NFKIRHNIEDGSVQLADHYQQNTPI
SEQ ID NO: 812	del15	NFKI-HNIEDGSVQLADHYQQNTPI
SEQ ID NO: 813	del16	NFKIR-NIEDGSVQLADHYQQNTPI
SEQ ID NO: 814	del18	NFKIRHN-EDGSVQLADHYQQNTPI
SEQ ID NO: 815	del 8-13	NFKIRHN-----QLADHYQQNTPI
SEQ ID NO: 816	del 1-5	-----HNIEDGSVQLADHYQQNTPI
SEQ ID NO: 817	del 15-25	NFKIRHNIEDGSVQ-----

FIG. 29D



364

44/266




FIG. 31




FIG. 32

45/266




FIG. 33




FIG. 34

47/266




FIG. 35A




FIG. 35B

48/266




FIG. 36

49/266




FIG. 37A

50/266





FIG. 37B




FIG. 38B

52/266




FIG. 38C




FIG. 38D

53/266




FIG. 38E






FIG. 38F






FIG. 39C




FIG. 39D





FIG. 40A






FIG. 40C




FIG. 41A

61/266




FIG. 41C




FIG. 41B

62/266




FIG. 41E

FIG. 41D

63/266




FIG. 41G




FIG. 41F




FIG. 41H




FIG. 411




FIG. 41K




FIG. 41J

67/266




FIG. 42A




FIG. 42B




FIG. 42C




FIG. 42D




FIG. 42E




FIG. 42F

70/266




FIG. 42G




FIG. 42H




FIG. 43A




FIG. 43B




FIG. 43C

73/266




FIG. 43D




FIG. 43E

74/266




FIG. 43F




FIG. 43G

75/266




FIG. 43H




FIG. 43I




FIG. 44C

78/266






FIG. 44D




FF44G

LE 44 G




44



45A
G^x
E

81/266






FIG. 45C




FIG. 45D




FIG. 45E




FIG. 45F




FIG. 45G

85/266




FIG. 46A

86/266




FIG. 46B




FIG. 46C

87/266




FIG. 46D




FIG. 46E

88/266




FIG. 46F

PE1	Cas9 H840A-M-MLV RT (wt)
PE1-M1	Cas9 H840A-M-MLV RT (D200N)
PE1-M2	Cas9 H840A-M-MLV RT (D200N+L603W)
PE1-M3	Cas9 H840A-M-MLV RT (D200N+L603W+T330P)
PE1-M6	Cas9 H840A-M-MLV RT (D200N+L603W+T330P+D524G+E562Q+D583N)
PE1-M15	Cas9 H840A-M-MLV RT (P51L+S67R+E67K+T197A+H204R+E302K+F309N+W1331F+T330P+L345G+N454K+D524G+D583N+H594Q+D653N)
PE1-M3inv	M-MLV RT (D200N+L603W+T330P)-Cas9 H840A
PE2	Cas9 H840A-M-MLV RT (D200N+L603W+T330P+T306K+W313F)

FIG. 47A

89/266




FIG. 47B




FIG. 47C




FIG. 47D




FIG. 47E

91/266




FIG. 47F




FIG. 47G

92/266




FIG. 47H




FIG. 47I

93/266




FIG. 47J




FIG. 47K

94/266




FIG. 47L




FIG. 47M

95/266




FIG. 47N




FIG. 47O

96/266




FIG. 47P




FIG. 47Q

97/266




FIG. 47R




FIG. 47S

98/266




FIG. 48A




FIG. 48B




FIG. 48C

99/266




FIG. 49A




FIG. 49B

100/266




FIG. 50A




FIG. 50B




FIG. 51A




FIG. 51B




FIG. 51C




FIG. 51D




FIG. 51E

105/266

SEQ ID NO:

791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-Reference
K562 HEK3 negative control (non-targeting pegRNA)				
791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-93.54% (47190 reads)
791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-0.47% (238 reads)
829	TGGGGCCCAGACTGAGC	CACGTGATGGCAG	CAGGAAAGGAAG	-0.21% (108 reads)
K562 HEK3 PE3+1 CTT insertion				
791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-69.66% (39061 reads)
830	TGGGGCCCAGACTGAGC	CACGCTTTGATGGCAGAGG	AAAGGAAG	-22.80% (12784 reads)
791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-0.32% (179 reads)
830	TGGGGCCCAGACTGAGC	CACGCTTTGATGGCAGAGG	AAAGGAAG	-0.21% (120 reads)
831	TGGGGCCCAGACTGAGC	CACGCTTTTATGGCAGAGG	AAAGGAAG	-0.21% (116 reads)
K562 HEK3 Cas9-initiated HDR +1 CTT insertion				
832	TGGGGCCCAGACTGAGC	AC-TGATGGCAGAGG	AAAGGAAG	-17.15% (7256 reads)
791	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-13.86% (5864 reads)
830	TGGGGCCCAGACTGAGC	CACGCTTTGATGGCAGAGG	AAAGGAAG	-10.55% (4461 reads)
833	TGGGGCCCAGACTGAGC	AA-TGATGGCAGAGG	AAAGGAAG	-9.72% (4111 reads)
834	TGGGGCCCAGACTGAGC	ACG--ATGGCAGAGG	AAAGGAAG	-5.14% (2174 reads)
835	TGGGGCCCAGACTGAGC	CACGCTGATGGCAGAGG	AAAGGAAG	-4.77% (2016 reads)
836	TGGGGCCCAGACTGAGC	ACG-GATGGCAGAGG	AAAGGAAG	-3.82% (1616 reads)
837	TGGGGCCCAGACTGAGC	CACGTGATGGCAGAGG	AAAGGAAG	-3.17% (1342 reads)
838	TGGGGCCCAGACTGA	-----TGGCAGAGG	AAAGGAAG	-1.92% (814 reads)
839	TGGGGCCCAGACTGAGC	CACGATGATGGCAGAGG	AAAGGAAG	-1.63% (689 reads)
840	TGGGGCCCAGACTGAGC	ACG-----CAGAGG	AAAGGAAG	-1.26% (535 reads)
841	TGGGGC	-----TGATGGCAGAGG	AAAGGAAG	-0.78% (329 reads)
842	TGGGGCCCAGACTGAGC	AA-----GAGG	AAAGGAAG	-0.61% (257 reads)
843	TGGGGCCCAGACTGAGC	ACGCTGATGGCAGAGG	AAAGGAAG	-0.59% (250 reads)
844	TGGGGCC	-----TGATGGCAGAGG	AAAGGAAG	-0.56% (237 reads)

FIG. 51F

106/266

845	TGGGG	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.52% (219 reads)		
846	TGGGG	CCCAGACTGAGCACG	-----	-----	AGCAA	GGAAG	-0.47% (197 reads)		
847	TGGGG	CCCAGACTGAGCACG	-----	-----	AGAGG	AAA	GGAAG	-0.43 (181 reads)	
848	TGGGG	CCCAGACTGAGCACG	-----	GGCAGAGG	AAA	GGAAG	-0.41 (173 reads)		
849	TGGGG	CCCAGACTGAG	-----	-----	GAAA	GGAAG	-0.40% (169 reads)		
850	TGGGGC	-----	-----	-----	AGAGG	AAA	GGAAG	-0.38% (159 reads)	
851	TGGGG	CCCAGACTGAGCACG	-----	-----	GAAA	GGAAG	-0.37% (156 reads)		
852	TGGGG	CCCAG	-----	-----	TGGCAGAGG	AAA	GGAAG	-0.35% (148 reads)	
853	TGGGG	CCCAGACTGAGCACG	-----	-----	AAA	GGAAG	-0.35% (146 reads)		
854	TC	-----	-----	-----	ATGGCAGAGG	AAA	GGAAG	-0.31% (132 reads)	
855	TGGGG	CCCAGACTGAGCTT	-----	TGATGGCAGAGG	AAA	GGAAG	-0.30% (125 reads)		
856	TGGGG	CCCAGACTGAGCACG	-----	-----	-----	AA	-0.30% (125 reads)		
857	TGGGG	CCCAGACTGAGCACG	-----	-----	-----	GAGG	AAA	GGAAG	-0.29% (122 reads)
858	TGGGG	CCCAGACTGAGCACG	-----	-----	-----	GA	-0.29% (121 reads)		
859	TGGGG	CCCAG	-----	-----	-----	GG	AAA	GGAAG	-0.27% (114 reads)
860	TGGGG	CCCAG	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.26% (112 reads)	
861	TGG	-----	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.26% (112 reads)	
862	TGGGG	CCCAGACTGAGCACG	-----	TGATGGCAGAGG	AAA	GGAAG	-0.26% (110 reads)		
863	-----	-----	-----	-----	ATGGCAGAGG	AAA	GGAAG	-0.24% (100 reads)	
864	TGGGG	CCCAGACTG	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.23% (96 reads)	
865	TGGGG	CCCAGACTGAG	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.23% (96 reads)	
866	TGGGG	CCC	-----	-----	TGATGGCAGAGG	AAA	GGAAG	-0.22% (93 reads)	
867	TGGGG	CCCAGACTGAGCACG	-----	-----	GCAGAGG	AAA	GGAAG	-0.21% (87 reads)	

bold Substitutions

 Insertions

- Deletions

---- Predicted

cleavage position

FIG. 51G

107/266




FIG. 52A




FIG. 52B




FIG. 52C






FIG. 52D

109/266



110/266

Line 1
SEQ ID NO:

868	C	C	T	G	A	A	C	C	G	T	A	T	A	T	C	C	T	A	T	G	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-Reference
869	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-92.16% (28182 reads)
870	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-1.54% (471 reads)
871	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-1.10% (335 reads)	
872	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	C	T	T	T	C	-0.94% (288 reads)		
869	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-0.61% (188 reads)	
873	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	C	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	C	-0.51% (156 reads)

Line 2

868	C	C	T	G	A	A	C	C	G	T	A	T	A	T	C	C	T	A	T	G	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-Reference
869	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-91.74% (18375 reads)	
870	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-1.34% (269 reads)
871	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-1.08% (217 reads)	
872	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	C	T	T	T	C	-0.85% (171 reads)		
869	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	C	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	C	-0.59% (119 reads)
868	C	C	T	G	A	A	C	C	G	T	A	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-0.57% (115 reads)	
869	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	G	C	C	T	G	A	C	T	G	G	A	A	G	G	A	T	T	T	C	-0.53% (106 reads)	
874	A	A	C	C	G	T	A	T	A	T	C	T	A	T	C	C	T	A	T	C	T	G	C	C	T	G	A	C	T	G	G	A	A	G	C	T	T	T	C	-0.23% (47 reads)

bold Substitutions
□ Insertions
- Deletions
---- Predicted cleavage position

FIG. 53C

111/266

Line 1
SEQ ID NO:

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-97.45% (87424 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.27% (240 reads)
877	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.24% (212 reads)

Line 2

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-97.16% (63793 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.36% (239 reads)
877	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.22% (142 reads)

Line 3

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-97.32% (77514 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.29% (228 reads)
877	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.22% (172 reads)
878	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	T	C	G	T	T	-0.21% (167 reads)

Line 4

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-96.94% (70061 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.58% (419 reads)
877	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	C	C	G	T	T	-0.23% (165 reads)
878	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	G	T	C	T	G	T	C	G	T	T	-0.21% (150 reads)

FIG. 53D

Line 5

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-97.16% (54265 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-0.33% (183 reads)
877	C	A	C	C	A	T	G	G	C	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-0.21% (120 reads)
878	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	A	G	T	C	T	G	T	C	G	T	T	-0.20% (113 reads)

Line 6

875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-Reference
876	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-97.35% (95642 reads)
875	C	A	C	C	A	T	G	G	T	G	C	A	C	C	T	G	A	C	T	C	C	T	G	A	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-0.27% (267 reads)
877	C	A	C	C	A	T	G	G	C	G	C	A	C	C	T	G	A	C	T	C	C	T	G	T	G	G	A	G	A	A	G	T	C	T	G	C	C	G	T	T	-0.21% (211 reads)

bold Substitutions

Insertions

- Deletions

---- Predicted cleavage position

FIG. 53E

114/266




FIG. 55A




FIG. 55B




FIG. 55C




FIG. 55D




FIG. 55E




FIG. 55F




FIG. 55G




FIG. 56A




FIG. 56B




FIG. 56C

120/266




FIG. 57A

121/266




FIG. 57B




FIG. 57C

123/266




FIG. 57D

124/266




FIG. 57E

125/266




FIG. 57F

126/266




FIG. 57G

127/266




FIG. 57H




FIG. 57I





FIG. 58A



130/266

Cloning overview

1. **Digest pU6-pegRNA-GG-Vector plasmid (component 1)** with *BsaI* and isolate the plasmid fragment (~2.2kb) containing the origin of replication, U6 promoter, U6 poly-T termination sequence, and Amp^R gene
2. **Order oligonucleotides for:**
 - a. The desired spacer (target) sequence flanked by indicated overhangs (**component 2**)
 - i. Use the desired target's 5'-3' sequence for the top strand oligonucleotide (including the 5' CACC and 3' GTTTT overhangs) and use the reverse complement of the target sequence for the bottom strand oligonucleotide (including the 5' CTCTAAAC overhang). Spacer sequences must begin with a G nucleotide for efficient transcription initiation.
 - b. The desired pegRNA 3' extension template flanked by the indicated overhangs (**component 3**)
 - i. Use the RNA sense sequence as the top strand oligonucleotide (featuring the 5' GTGC overhang) and use the reverse complement of this sequence for the bottom strand oligonucleotide (featuring the 5' AAAA overhang).
 - c. SpCas9 sgRNA scaffold sequence featuring compatible golden gate overhangs (**component 4**)
 - i. These oligonucleotides are not the complete scaffold sequence, as overhangs from the remaining components contribute several missing nucleotides
 - ii. Note: these oligonucleotides must be 5' phosphorylated. Oligonucleotides can be 5' phosphorylated by the manufacturer or 5' phosphorylated enzymatically using T4 PNK (see protocol below)
3. **Anneal top and bottom oligonucleotides** for components 2, 3, and 4 in separate annealing reactions according to the protocol below. If the SpCas9 sgRNA scaffold sequence (component 4) was not phosphorylated, phosphorylate with T4 PNK.
4. **Golden Gate assembly of isolated 2.2-kb fragment from component 1 with components 2, 3, and 4**
5. **Transform the ligation product into *E. coli*.** The antibiotic resistance conferred by component 1 from the pU6-pegRNA-GG-vector plasmid is ampicillin and carbenicillin resistance.
6. **Isolate and sequence plasmids** from the resulting clonal transformants

FIG. 59ApegRNA cloning protocol**Step 1: Digest pU6-pegRNA-GG-Vector plasmid (component 1)**

Combine the following in a PCR tube:

2000 ng pU6-pegRNA-GG-Vector (component 1)	X µL
Bsa1-HFv2 (NEB)	1.0 µL
10x Cutsmart Buffer	3.0 µL
H ₂ O	to 30.0 µL
Total reaction volume	30.0 µL

Incubate at 37 °C for 4-16 hours

Isolate ~2.2-kb fragment from cut plasmid.

FIG. 59B

131/266

Steps 2 and 3: Order and anneal oligonucleotide parts (components 2, 3, and 4)MaterialsAnnealing buffer: H₂O supplemented with 10 mM Tris-Cl pH 8.5 and 50 mM NaCl

Complementary oligonucleotide pairs

Protocol

Combine the following in a PCR tube:

Top oligonucleotide, 100 μ M	1.0 μ L
Bottom oligonucleotide, 100 μ M	1.0 μ L
Annealing buffer (components 2, 3, and 4)	23.0 μ L
<hr/>	
Total reaction volume	25.0 μ L

In thermocycler, heat at 95 °C for 3 minutes, then cool gradually (0.1 °C/s) to 22 °C

Dilute annealed oligonucleotides 1:4 by adding 75 μ L H₂O. The final concentration of each oligonucleotide will be 1 μ M after this dilution. Do not dilute the sgRNA scaffold (component 4) if phosphorylating by PNK in step 2.5.**FIG. 59C****Step 2.b.ii.: sgRNA scaffold phosphorylation (unnecessary if oligonucleotides were purchased phosphorylated)**Protocol

Combine the following in a PCR tube:

4 μ M oligonucleotide duplex from step 1	6.25 μ L
10x T4 DNA ligase buffer (NEB)	2.50 μ L
T4 PNK (NEB)	0.50 μ L
H ₂ O	15.75 μ L
<hr/>	
Total reaction volume	20.0 μ L

In thermocycler, incubate at 37 °C for 60 minutes

Following this phosphorylation, annealed scaffold oligonucleotides are now at a concentration of 1 μ M.

Proceed to step 3.

FIG. 59D

132/266

Step 4: peg RNA assemblypegRNA, Golden Gate assembly reaction

Digested pU6-pegRNA-GG plasmid-vector	1.00 μ L @ 30 ng/ μ L
- Pre-cut, isolated 2.2-kb fragment	
Annealed protospacer oligonucleotides (component 2)	1.00 μ L @ 1 μ M
Annealed pegRNA 3'-extension oligonucleotides (component 4)	1.00 μ L @ 1 μ M
sgRNA scaffold annealed oligonucleotides (component 3)	1.00 μ L @ 1 μ M
- Oligonucleotides must be phosphorylated	
<i>Bsa</i> I-HFv2 (NEB)	0.25 μ L
T4 DNA ligase (NEB)	0.50 μ L
10x T4 DNA ligase buffer (NEB)	1.00 μ L
H ₂ O	4.25 μ L
<hr/>	
Total reaction volume:	10.0 μ L

Incubate at room temperature for 10 min

Following incubation, perform the following program in a thermocycler:

5 min at 37 °C then 5 min at 80 °C then hold at 12 °C

FIG. 59E**Steps 5 and 6: Transformation of assembled plasmids**

Transform 1 μ L of the 10 μ L assembly reaction into 10 μ L of competent cells. The desired transformants will be resistant to ampicillin and carbenicillin.

The following diagram summarizes the pegRNA cloning protocol.

FIG. 59F

134/266

```

## sgRNA scaffold sequence search ##

import pandas as pd
import Bio as bio
from Bio import SeqIO
import glob

#generates list of fastq files to analyze
sources = glob.glob("*.fastq")

#reads the fastq files into a dictionary with the file names as keys
fastqdict = {}
for i in range(len(sources)):
    temp = list(SeqIO.parse(sources[i], "fastq"))
    fastqdict[sources[i]] = [str(temp[k].seq) for k in range(len(temp))]

#the referenced sequence to be searched for is entered into the following dictionary with
#an appropriate key
scaffdict =
{'HEK3':'CAGAGGACCGACTCGGTCCCACCTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTT
GCTATTTCTAGCTCTAAAACTCACGTGCTCAGTCTGGGCCGGTG', (SEQ ID NO: 885)
'EMX1':'ATCAGCACCGACTCGGTGCCACTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACT
TGCTATTTCTAGCTCTAAAACTTCTTCTTCTGCTCGGACTCGGTG', (SEQ ID NO: 886)
'FANCF':'TTTCCGCACCGACTCGGTGCCACTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACT
TTGCTATTTCTAGCTCTAAACGGTGCTGCAGAAGGGATTCCGGTG', (SEQ ID NO: 887)
'RNIF2':'TCGTTGCACCGACTCGGTGCCACTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTT
GCTATTTCTAGCTCTAAACCGGTAATGACTAAGATGACGGTG') (SEQ ID NO: 888)

#matches and counts iterative slices of the reference string to the appropriate fastq files
#reference key must be contained in the name of the fastq file
#generated values represent cumulative counts for a minimum degree of sgRNA integration
#i.e. a given value x means x reads contain y or more bases of the scaffold
resultdict = dict.fromkeys(sources)
for key in fastqdict:
    for scaffold in scaffdict:
        if scaffold in str(key):
            resultlist = []
            for j in range(len(scaffdict[scaffold])):

```

FIG. 60A

135/266

```

        extent = scaffold[scaffold][0:(j+1)]
        counter = 0
        for i in range(len(fastqdict[key])):
            if extent in fastqdict[key][i]:
                counter = counter + 1
        resultlist.append(counter)
        resultdict[key]=resultlist

#writes the results into a dataframe indexed from 1
resultdf = pd.DataFrame.from_dict(resultdict)
resultdf = resultdf.reindex(sorted(resultdf.columns), axis=1)
resultdf.index = range(1,len(resultdf)+1)

#converts the cumulative count values into specific counts
#i.e. a given value x means x reads contain exactly y bases of the scaffold
resultdf2=resultdf.copy()
for entry in resultdf:
    for i in range(1,len(resultdf[entry])+1):
        try:
            resultdf2[entry][i] = resultdf[entry][i]-resultdf[entry][i+1]
        except:
            resultdf2[entry][i] = resultdf[entry][i]

#converts the specific counts values into frequencies
resultdf3=resultdf2.copy()
for entry in resultdf3:
    resultdf3[entry]=resultdf2[entry].div(resultdf[entry][1])*100

#reads the results into excel files
resultdf.to_excel('cumulativecounts.xlsx')
resultdf2.to_excel('specificcounts.xlsx')
resultdf3.to_excel('specificfrequencies.xlsx')

```

FIG. 60B




FIG. 62A

FIG. 61





FIG. 62B



139/266




FIG. 64A




FIG. 64B



FIG. 64C



FIG. 64D



FIG. 64E





FIG. 64F

140/266






FIG. 66

142/266




FIG. 67A

143/266

intein excision mechanism




FIG. 67B




FIG. 68A




FIG. 68B

145/266




FIG. 68C

146/266




FIG. 69

147/266

Starting allele

(SEQ ID NO: 892)

5'- TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

Edit Target (A→T to C→G)

ATGCCCCCTGGCAGTCATCTTAGTCATTACCTGAGGTGTTGTTGTAACATATATAAACTGAGTTCC
TACGGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTTGACTCAAGG

CATGTTTTGCTTAATGGTTGAGTTCGGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAAACAGACGTGTCGGACTCTGTAACGACCTTTATTTCTTC

FIG. 70A

Starting allele

(SEQ ID NO: 892)

5'- TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

NGG PAM 1

ATGCCCCCTGGCAGTCATCTTAGTCATTACCTGAGGTGTTGTTGTAACATATATAAACTGAGTTCC
TACGGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTTGACTCAAGG

NGG PAM 2

CATGTTTTGCTTAATGGTTGAGTTCGGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAAACAGACGTGTCGGACTCTGTAACGACCTTTATTTCTTC

FIG. 70B

Starting allele

(SEQ ID NO: 892)

5'- TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

nick for PAM 1

ATGCCCCCTGGCAGTCATCTTAGTCATTACCTGAGGTGTTGTTGTAACATATATAAACTGAGTTCC
TACGGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTTGACTCAAGG

nick for PAM 2

CATGTTTTGCTTAATGGTTGAGTTCGGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAAACAGACGTGTCGGACTCTGTAACGACCTTTATTTCTTC

FIG. 70C

148/266

Starting allele

(SEQ ID NO: 892)

5'- TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

Spacer

ATGCCCTTGGCAGTCATCTTAGTCATTACCTCAGGTGTTTCGTTGTAACATATAAACTGAGTTCC
TACGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTGACTCAAGG

CATGTTTTGCTTAATGGTTGAGTTCCGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAACAGACGTGTCCGACTCTGTAACGACCTTTATTTCTTC

(SEQ ID NO: 637)

Spacer = GTCATCTTAGTCATTACCTG

FIG. 70D

Starting allele

(SEQ ID NO: 892)

5'- TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

PBS complement

ATGCCCTTGGCAGTCATCTTAGTCATTACCTCAGGTGTTTCGTTGTAACATATAAACTGAGTTCC
TACGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTGACTCAAGG

CATGTTTTGCTTAATGGTTGAGTTCCGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAACAGACGTGTCCGACTCTGTAACGACCTTTATTTCTTC

PBS = GTAATGACTAAGATG

FIG. 70E

Desired allele

(SEQ ID NO: 892) 5'-

TATTATTACTCTATGTTCTATTTAAGTTTTTCATGTTCTAAAAATGTATCCCAGTTTACACGTCTCAT
ATAATAATGAGATACAAGATAAATTCAAAAGTACAAGATTTTACATAGGGTCAAATGTGCAGAGTA

(SEQ ID NO: 893)

RT template complement

ATGCCCTTGGCAGTCATCTTAGTCATTACCTCAGGTGTTTCGTTGTAACATATAAACTGAGTTCC
TACGGGAACCGTCAGTAGAATCAGTAATGGACTCCACAAGCAACATTGAGTATATTGACTCAAGG

Edit

CATGTTTTGCTTAATGGTTGAGTTCCGTTTGTCTGCACAGCCTGAGACATTGCTGGAAATAAAGAAG -3'
GTACAAAACGAATTACCAACTCAAGGCAACAGACGTGTCCGACTCTGTAACGACCTTTATTTCTTC

SEQ ID NO: 1759

RT template = AACGAACACCGCAG

FIG. 70F

149/266




FIG. 70G




FIG. 70H



FIG. 70I

generic SpCas9 pegRNA



Condition	%PE	%indels
HEK3.30	~17.5	~1.0
HEK3.30.37	~21.5	~1.0
EMX1.ID3	~2.5	~1.0
EMX1.ID3.11	~6.5	~1.5

FIG. 71B




FIG. 72A




FIG. 72B





FIG. 72C






FIG. 74




FIG. 75

156/266




FIG. 76




FIG. 77




FIG. 78

158/266




FIG. 79




FIG. 80




FIG. 81




FIG. 82




FIG. 83

161/266




FIG. 84A




FIG. 84B




FIG. 85




FIG. 86




FIG. 87




FIG. 88

165/266




FIG. 89

166/266




FIG. 90A

167/266




FIG. 90B

168/266

pegRNA sequence: SEQ ID NO: 1762

GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGA
AAAGTGGCACCAGTCGGTGCTGGAGGAAGCAGGGCTTCCTTCTCTGCCATCACTTATCGTCGTCATCCTTGT
ATCCGTGCTCAGTCTG

Template amplicon sequence: SEQ ID NO: 1763

AAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCAGTCGGTGCTGGAGGAAGCAGGGCTTCCTTCT
TCTGCCATCACTTATCGTC

PBS amplicon sequence: SEQ ID NO: 1764

TGAAAAAGTGGCACCAGTCGGTGCTGGAGGAAGCAGGGCTTCCTTCTCTGCCATCACTTATCGTCGTCATCC
TGTAATCCGTGCTCAGTCTGT

FIG. 90C




FIG. 91A




FIG. 91B

170/266




FIG. 91C




FIG. 91D

171/266




FIG. 92A




FIG. 92B




FIG. 92C

173/266




FIG. 93A




FIG. 93B

174/266




FIG. 93C




FIG. 93D




FIG. 93E




FIG. 93F

176/266




FIG. 93G




FIG. 93H

177/266




FIG. 94

178/266




FIG. 95A




FIG. 95B

179/266


PE2
HEK3 +1 FLAG

FIG. 96

180/266





FIG. 97

181/266

pegRNA appended at 3' end with nucleic acid moiety**FIG. 98**

182/266

U6 promoter for enhanced transcription of pegRNAs




FIG. 99




FIG. 100




FIG. 100B

184/266




FIG. 100C




FIG. 100D

185/266




FIG. 100E

186/266




FIG. 101

187/266





FIG. 102

188/266




FIG. 103A




FIG. 103B




FIG. 103C

189/266




FIG. 104A




FIG. 104B




FIG. 104C




FIG. 105B




FIG. 105A




FIG. 105C




FIG. 105D

193/266




FIG. 106A




FIG. 106B

194/266




FIG. 106C




FIG. 106D

195/266




FIG. 106E




FIG. 106F




FIG. 106G




FIG. 106H

197/266

Installation of the protective
G127V mutation in *PRNP*
in HEK293T cells




FIG. 107A

Correction of the pathogenic
1278insTATC mutation in
HEXA in HEK293T cells




FIG. 107B

198/266

Correction of the pathogenic
1278insTATC mutation in HEXA
in patient-derived fibroblasts




FIG. 107C

PE2 installation of nine pathogenic and protective alleles
with unoptimized pegRNAs and epegRNAs in HEK293T cells




FIG. 107D

199/266




FIG. 107E

200/266




FIG. 108

201/266




FIG. 109A




FIG. 109B




FIG. 109C




FIG. 110

204/266




FIG. 111A




FIG. 111B




FIG. 111C

205/266




FIG. 111D




FIG. 111E




FIG. 111F

206/266




FIG. 111G




FIG. 111H

207/266




FIG. 111I




FIG. 111J

208/266




FIG. 111K




FIG. 112A




FIG. 112B

209/266




FIG. 112C

pegRNA site	HEK3 (PE3)					EMX1 (PE3)					FANCF (PE3)				
	...	pt min,	pt min,	del,	del,	...	pt min,	pt min,	del,	del,	...	pt min,	pt min,	del,	del,
		-	m	-	p		-	p	-	m		-	m	-	m
On-target		21.5 (4.0)	44.1 (11.7)	57.9 (2.8)	72.7 (4.7)		30.5 (1.1)	34.5 (1.1)	28.6 (0.8)	47 (0.5)		40.7 (4.2)	48.8 (3.7)	38.9 (6.4)	40.6 (6.3)
Off-target 1		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)
Off-target 2		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)
Off-target 3		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)
Off-target 4		<0.1 (<0.1)	<0.1 (0.1)	<0.1 (0.1)	<0.1 (0.1)		<0.1 (0.1)	<0.1 (0.1)	<0.1 (0.1)	<0.1 (0.1)		<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)	<0.1 (<0.1)

FIG. 113

211/266




FIG. 114A




FIG. 114B

212/266




FIG. 114C




FIG. 115A

213/266




FIG. 115B




FIG. 115C




FIG. 116A




FIG. 116B




FIG. 116D




FIG. 116C




FIG. 117A




FIG. 117B




FIG. 117C




FIG. 118




FIG. 119

222/266




FIG. 120A




FIG. 120B

223/266




FIG. 120C




FIG. 120D




FIG. 120E

225/266




FIG. 120F




FIG. 120G

226/266




FIG. 121A




FIG. 121B

227/266




FIG. 122A




FIG. 122B




FIG. 123




FIG. 124A

229/266




FIG. 124B

230/266




FIG. 124C

231/266




FIG. 125A




FIG. 125B

232/266




FIG. 125C




FIG. 125D




FIG. 125E




FIG. 126A




FIG. 126B




FIG. 127A

HEK293T [1/10 DNA transfected],
PE3, epegRNA,
scaffold comparison




FIG. 127B

236/266

HEK293T [1/10 DNA transfected], PE3,
epegRNA,
scaffold comparison




FIG. 127C

237/266




FIG. 128

238/266




FIG. 129

239/266





FIG. 130



241/266




FIG. 132

242/266





FIG. 133

243/266




FIG. 134





FIG. 135

245/266



PBS = 13 all

1814: unmodified

1815: linker only


1816: epegRNA with MS2 aptamer

1817-1819: no toehold, MS2 aptamer

1820-1831: toeholds of various strengths, MS2 aptamer

FIG. 136

246/266



1814: unmodified PBS 13

1815: linker only PBS 13

1816: epegRNA with MS2 aptamer PBS 13

PBS 17 all

1832-1833: unmodified; linker alone


1834-1837: no toehold, MS2 aptamer

1838-1846: toeholds of various strengths, MS2 aptamer

FIG. 137

247/266

PE3, pegRNA, ngRNA



PE3, sgRNA, pegRNA




FIG. 138




FIG. 139




FIG. 140




FIG. 141

SEQ ID NOS: 1948-1972




FIG. 142

252/266




FIG. 143




FIG. 144




FIG. 145




FIG. 146

Heatmap showing the percentage of total sequencing reads with the specified edit for different RT template lengths (Y-axis, 19 to 30) and PBS lengths (X-axis, 9 to 14). The color scale indicates the percentage of reads, ranging from 0% (white) to 20% (dark grey).




FIG. 147




FIG. 148




FIG. 150




FIG. 151




FIG. 152




FIG. 153

261/266




FIG. 154




FIG. 155




FIG. 156

262/266




FIG. 157




FIG. 158

263/266




FIG. 159

CDKL5 silent +1 C to T installation (c.1412delA site),
HEK293T




FIG. 160

264/266




FIG. 161




FIG. 162




FIG. 163




FIG. 164




FIG. 165